| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | June 30, 2025 4:30 P.M. |
| Form: | S-1 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | June 30, 2025 4:30 P.M. |
| Form: | S-1 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4 - ORAGENICS INC (0001174940) (Issuer)
4 - ORAGENICS INC (0001174940) (Issuer)
3 - ORAGENICS INC (0001174940) (Issuer)
Goldman Sachs initiated coverage of Oragenics with a rating of Neutral and set a new price target of $52.00
Advancing Brain-First Recovery Platform Toward Clinical MilestonesPioneering Intranasal Therapeutics for Concussion SARASOTA, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a pioneering biotechnology company striving to develop brain-targeted therapeutics through proprietary intranasal delivery technology, today shared key strategic and financial milestones achieved during the second quarter of 2025 and shortly thereafter. These successes underscore the company's momentum as it strives to transform neurotrauma care and advance its lead candidate, ONP-002, toward becoming the first FDA-approved pharmacological treatment for concussion. "We're not just developing anot
SARASOTA, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company pioneering intranasal drug delivery for neurological conditions, today announced the selection of Southern Star Research as its Clinical Research Organization (CRO) for the upcoming Phase IIa clinical trial of ONP-002, the company's lead drug candidate for concussion. Southern Star Research is a globally recognized, full-service CRO with a proven track record in delivering early-phase trials across Australia and Asia-Pacific. Their deep operational expertise, regulatory knowledge, and hands-on site management capabilities will support the execution of Oragenics' randomized
SARASOTA, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced it has entered into a manufacturing agreement with Sterling Pharma Solutions, an industry leading CDMO with multiple US-based development and manufacturing facilities. Oragenics has partnered with Sterling Pharma Solutions for the GMP production of its lead drug candidate, ONP-002, for the treatment of concussion. This agreement is expected to ensure Good Manufacturing Practice (GMP)-compliant drug product supply ahead of the planned Phase IIb clinical trials which the Company expects to start next year. T
8-K - ORAGENICS INC (0001174940) (Filer)
10-Q - ORAGENICS INC (0001174940) (Filer)
8-K - ORAGENICS INC (0001174940) (Filer)
SARASOTA, Fla., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, proudly announces that its Chief Medical Officer, Dr. James Kelly, has been appointed to the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health. The Leigh Steinberg Foundation is dedicated to advancing brain health by supporting research, raising awareness, and driving actionable solutions for those affected by concussions and traumatic brain injuries (TBI). Dr. Kelly's appointment to the Medical Board reflects his leadership in brain injury resear
SARASOTA, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today provided an update on its strategic progress since its last capital raise in September 2024. The Company also announced the appointment of Janet Huffman as its new interim Chief Executive Officer. Strategic Progress Since Capital Raise Following the Company's $4 million capital raise in September 2024, the Company has made significant advancements, including: Formulation and Device Enhancements: The Company has improved the formulation and intranasal delivery device for ONP-002 and in connection therewith
SARASOTA, Fla., May 22, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has appointed Dr. William "Frank" Peacock as its Chief Clinical Officer, who will conduct its anticipated Phase II clinical trial for treating concussion in the Emergency Department ("ED"). Oragenics' lead drug candidate, ONP-002, is combined with its intranasal device intended for the treatment of mild Traumatic Brain Injury (mTBI), commonly known as concussion, in the field and emergency departments. ONP-002 is a new chemical entity (NCE) designed to target the brain through deliver
SC 13G/A - ORAGENICS INC (0001174940) (Subject)
SC 13G/A - ORAGENICS INC (0001174940) (Subject)
SC 13G - ORAGENICS INC (0001174940) (Subject)
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced it has raised approximately $20 million from the sale of common stock through a sales agreement with A.G.P./Alliance Global Partners for an “at-the-market” facility. In addition, the Company also received approximately $1.9 million from the exercise of common stock warrants. In turn, Oragenics has given a notice for the redemption of all outstanding shares of the Company’s Series C, Non-Convertible, Preferred Stock (the “Series C Preferred Stock”) to the holder of the Series C Preferred Stock. Commenting on these developments, Alan Joslyn, President and Chief Executive Offic